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Abstract
Background and purpose: New- onset refractory status epilepticus (NORSE) is a clinical 
presentation, neither a specific diagnosis nor a clinical entity. It refers to a patient with-
out active epilepsy or other pre- existing relevant neurological disorder, with a NORSE 
without a clear acute or active structural, toxic or metabolic cause. This study reviews 
the currently available evidence about the aetiology of patients presenting with NORSE 
and NORSE- related conditions.
Methods: A systematic search was carried out for clinical trials, observational studies, 
case series and case reports including patients who presented with NORSE, febrile- 
infection- related epilepsy syndrome or the infantile hemiconvulsion- hemiplegia and epi-
lepsy syndrome.
Results: Four hundred and fifty records were initially identified, of which 197 were in-
cluded in the review. The selected studies were retrospective case– control (n = 11), 
case series (n = 83) and case reports (n = 103) and overall described 1334 patients both 
of paediatric and adult age. Aetiology remains unexplained in about half of the cases, 
representing the so- called ‘cryptogenic NORSE’. Amongst adult patients without cryp-
togenic NORSE, the most often identified cause is autoimmune encephalitis, either non- 
paraneoplastic or paraneoplastic. Infections are the prevalent aetiology of paediatric 
non- cryptogenic NORSE. Genetic and congenital disorders can have a causative role in 
NORSE, and toxic, vascular and degenerative conditions have also been described.
Conclusions: Far from being a unitary condition, NORSE is a heterogeneous and clinically 
challenging presentation. The development and dissemination of protocols and guide-
lines to standardize diagnostic work- up and guide therapeutic approaches should be im-
plemented. Global cooperation and multicentre research represent priorities to improve 
the understanding of NORSE.
K E Y W O R D S
Febrile- infection- related epilepsy syndrome, infantile hemiconvulsion- hemiplegia and epilepsy 
syndrome, NORSE, seizures, status epilepticus
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INTRODUC TION
Status epilepticus (SE) is a condition resulting either from the failure 
of the mechanisms responsible for seizure termination or from the 
initiation of mechanisms leading to abnormally prolonged seizure ac-
tivity [1]. It is an important neurological emergency and a potentially 
life- threatening condition [2]. Current treatment protocols are based 
on a three- stage approach, with benzodiazepines generally recom-
mended as first- line agents, intravenous antiseizure medications as 
second- line and anaesthetics as third- line [3]. Refractory SE (RSE) 
is defined as a failure of first- line therapy with benzodiazepines 
and one second- line treatment with antiseizure medications, and 
in super- refractory SE (SRSE) status continues or recurs despite the 
use of anaesthetics for longer than 24 h [4,5].
Almost half of patients experiencing SE suffer from known epi-
lepsy, and an obvious cause can be identified in many others [6– 8]. 
Some cases, however, elude any easily detectable aetiology and pre-
viously healthy individuals develop prolonged RSE without a readily 
identifiable explanation. This form of presentation has been given 
different terms and acronyms suggesting a separate entity or dis-
ease. The lack of a clear concept of the nosology and the absence 
of standardized terminology has hampered multicentre investiga-
tions and generated confusion in the literature and at the bedside. 
Recently, a consensus definition has been proposed to clearly define 
new- onset RSE (NORSE) and other related disorders [9]. The mul-
tidisciplinary group of experts highlighted that NORSE is ‘a clinical 
presentation, not a specific diagnosis, in a patient without active 
epilepsy or other pre- existing relevant neurological disorder, with 
a new onset of RSE without a clear acute or active structural, toxic, 
or metabolic cause’ [9]. Febrile- infection- related epilepsy syndrome 
(FIRES) is a subcategory of NORSE that requires a prior febrile infec-
tion, with fever starting between 2 weeks and 24 h prior to the onset 
of RSE, with or without fever at SE onset [9]. There is no age limita-
tion for NORSE or FIRES, and both adults and children can present 
NORSE and FIRES.
In recent years, NORSE has become increasingly well recognized, 
and progress has been made in aetiological characterization with dif-
ferent causes identified in many cases. This study aims to systemat-
ically review the currently available evidence about the aetiology of 
NORSE and NORSE- related conditions.
METHODS
The results of this systematic review are reported according to the 
recommendations of the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) statement and the Synthesis 
Without Meta- analysis (SWiM) in systematic reviews extension 
[10,11]. The relevant studies were identified through MEDLINE (ac-
cessed by PubMed as of April 2021, week 1). The search terms were 
combinations of the following: ‘new onset refractory status epi-
lepticus’, ‘febrile infection related epilepsy syndrome’, ‘devastating 
epileptic encephalopathy school aged children’, ‘acute encephalitis 
refractory repetitive partial seizures’, ‘fever induced refractory epi-
leptic encephalopathy school aged children’, ‘idiopathic catastrophic 
epileptic encephalopathy presenting acute onset intractable status’, 
‘severe refractory status epilepticus presumed encephalitis’ and 
‘infantile hemiconvulsion hemiplegia epilepsy syndrome’. The full 
search strategy is outlined in the Supporting Information. Additional 
data were sought at the NORSE institute website (http://www.
norse insti tute.org). There were no date limitations or language re-
strictions; English- language titles and abstracts were used if authors 
were not proficient enough in the published language to screen for 
inclusion of the studies or extract relevant data. The protocol was 
not registered previously.
The following types of studies were considered for inclusion: 
randomized or non- randomized clinical trials; observational case– 
control, cohort or cross- sectional studies; case series or case re-
ports. Reviews, meta- analyses, editorials, commentaries and expert 
opinions were excluded. Studies were included if patients met the 
diagnostic criteria for NORSE or FIRES [9]. To take into account the 
phenotypic similarities with FIRES that have been reported world-
wide in the literature under different terms over time [12], the follow-
ing diagnoses were also considered: idiopathic catastrophic epileptic 
encephalopathy presenting with acute onset intractable status [13]; 
severe refractory status epilepticus because of presumed enceph-
alitis [14]; devastating epileptic encephalopathy in school- aged 
children [15]; acute encephalitis with refractory, repetitive partial 
seizures [16]; fever induced refractory epileptic encephalopathy in 
school- aged children [17]. The Infantile Hemiconvulsion- Hemiplegia 
and Epilepsy syndrome (IHHE) was also included as this entity has 
recently been included amongst the NORSE- related conditions and 
defined as ‘a specific syndrome in a patient <2 years old, present-
ing as NORSE with unilateral motor seizures, high grade fever at the 
time of onset of refractory status epilepticus, and unilaterally ab-
normal acute imaging, followed by hemiparesis lasting at least 24 h 
and excluding definite infectious encephalitis’ [9]. Participants of any 
age, that is, paediatric and adult patients, sex and ethnicity were el-
igible. Two review authors (CR, SS) independently assessed studies 
for inclusion and any disagreement was resolved by discussion with 
a third review author (SL). The following information from included 
studies was extracted: first study author and age of publication, 
number and demographics of participants, diagnostic work- up and 
aetiologies identified in individual patients. The risk of bias of any 
included clinical trial was assessed using the RoB 2 tool [18], whilst 
it was not assessed individually for other study types (observational 
studies and case series/case reports) that, instead, were considered 
at high risk of bias [19].
RESULTS
Four hundred and fifty records were initially identified. Two hun-
dred and sixty- five studies were retrieved for detailed assessment, 
of which 197 were included in the review (Figure 1). The selected 
studies were retrospective case– control (n = 11), case series (n = 83) 
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and case reports (n = 103); there were no randomized or non- 
randomized clinical trials. All included studies were considered to 
have a high risk of bias related to the retrospective design, selection 
of participants, ascertainment of exposure, data collection and miss-
ing data, and reporting of results.
The studies overall described 1334 patients both of paediatric 
and adult age. The list of references to included studies can be found 
in the Supporting Information.
The diagnostic evaluations reported across the studies are 
shown in Figure 2. The work- up performed to identify the under-
lying aetiologies differed markedly between the studies and great 
heterogeneity can be observed in the type of investigations adopted 
to evaluate the patients. Infectious and autoimmune/paraneoplastic 
panels were the most commonly performed diagnostic examinations 
being reported in 157/197 (79.7%) and 120/197 (60.9%) studies, 
respectively; genetic tests were described in 36 (18.3%) of the in-
cluded studies. Amongst the advanced brain imaging techniques, 
brain positron emission tomography and single- photon emission 
computed tomography were the most often utilized, being reported 
in 16/197 (8.1%) and 7/197 (3.6%) studies. Amongst histopatholog-
ical examinations, cerebral biopsy was the most frequent required 
and performed in 15/197 (7.6%) studies. Available details about 
autoimmune and infectious panels, advanced imaging techniques, 
genetic tests and histopathological analyses performed within the 
diagnostic work- up of the studies are summarized in Table S1.
In the included reports, the aetiology of NORSE remained un-
known in the majority of cases; the most frequent causes identified 
in patients described in the studies were autoimmune and infectious 
disorders. The aetiologies recognized in all studies included in the 
review are shown in Table 1.
DISCUSSION
New- onset refractory status epilepticus is a heterogeneous pres-
entation of a variety of conditions and diseases. Based on the co-
hort studies with the largest population both in the paediatric and 
adult age groups, aetiology remains unexplained, despite an exten-
sive, albeit variable diagnostic work- up, in about half of the cases 
representing the so- called ‘cryptogenic NORSE’ (c- NORSE) [20,21]. 
Amongst adult patients with symptomatic rather than c- NORSE, the 
most commonly identified cause is autoimmune encephalitis, either 
non- paraneoplastic or paraneoplastic. Different antibodies against 
neuronal surface or intracellular antigens have been associated 
with subtypes of autoimmune encephalitis, and their pathogenicity 
varies.
Antibodies directed against neuronal cell surface antigens are di-
rectly pathogenic, and they include antibodies against the N- methyl- 
d- aspartate receptor (NMDAR), leucine- rich glioma- inactivated 1 
(LGI1) and γ- aminobutyric acid B receptor (GABABR) [22]. Although 









Irrelevance (reviews, editorials, 
commentaries, expert opinions, surveys, 
unrelated to topic)










F I G U R E  2  Diagnostic work- up in 
included studies. Laboratory, instrumental 
and histopathological tests reported as 
part of the diagnostic work of patients 
with NORSE and NORSE- related 
conditions. Percentages of studies 
out of the 197 included are shown. 
MEG, magnetoencephalography; MRI, 
magnetic resonance imaging; NORSE, 
new- onset refractory status epilepticus; 
PET, positron emission tomography; 
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TA B L E  1  Main characteristics of all studies included in the review and aetiologies identified in patients with NORSE and NORSE- related 
conditions
Study Study design Population Prodromes Aetiology
Acharya et al., 2015 [79] Case report Male, 45 years== Triazophos poisoning
Agarwal et al., 2015 Case report aMale, 4 years Sinus infection, fever Unknown
Agarwal et al., 2018 Case report Male, 23 years Fever, painless complete vision loss Infection by simian virus 40








Checkpoint inhibitor- induced 
autoimmune encephalitis
Akiyama et al., 2020 Case report Male, 84 years Encephalitis associated with anti- 
GABAB receptor antibodies (in 
small cell lung cancer)
Al- Khateeb et al., 2019 Case report Male, 41 years Blurry vision, headache Antiphospholipid syndrome
Alkhachroum et al., 2020 Case series N = 12 Unknown
Alparslan et al., 2017 Case report aMale, 8 years Fever, upper respiratory infection Unknown




Appenzeller et al., 2012 
[38]
Case series aN = 15, 
male:female 
= 8:7, median 
age 6 (range 
3– 15) years
Fever (1/15)
Febrile rhinovirus bronchitis (1/15)
Febrile tonsillitis (1/15)
Febrile upper respiratory infections 
(3/15)
Subfebrile temperature, vomiting 
and headache (1/15)
Febrile parvovirus B19 infection 
(1/15)
Febrile pneumonia (1/15)
Fever and headache (2/15)
Febrile pharyngitis (1/15)
Febrile enteritis (2/15)
Febrile cervical lymphadenitis (1/15)
Unknown; one potentially 
functionally relevant mutation 
in POLG affecting a splice site 
variant (c.1251- 5C>G) was 
identified
Arayakarnkul et al., 2018 Case series N = 10, male:female 





with autoimmune thyroiditis 
(2/10)
Neuropsychiatric systemic lupus 
erythematosus (1/10)












Flu- like symptoms, headache, 
abdominal discomfort, diarrhoea
Fever, headache, nausea, sores on 
lips
Fever, abdominal pain, vomiting
Feeling drowsy
Vomiting, fever










Encephalitis associated with anti- 
GAD and GABABR antibodies
Baba et al., 2021 Case report aFemale, 8 years Fever, diarrhoea, anorexia Unknown
(Continues)
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Study Study design Population Prodromes Aetiology
Babi et al., 2017 [81] Case report Male, 40 years Exposure to synthetic 
cannabinoids
Baxter et al., 2003 [13] Case series bN = 6, male:female 
= 4:2, age range 
5 months to 
6 years
Non- specific symptoms suggestive 
of infection (4/6), fever (2/6)
Unknown
Boyd et al., 2010 Case report Male, 26 years Headache, fever, myalgias Unknown
Boyd et al., 2012 Case report Female, 22 years Fever, malaise Unknown
Brunker et al., 2020 Case report Male, 18 years Flu- like symptoms, fatigue CSF positivity of anti- GAD 
antibodies
Byler et al., 2014 Case report aMale, 5 years Fever, coryza, diarrhoea Unknown
Cantarín Extremera et al., 
2020 [71]
Case report aMale, 9 years Fever Increased serum and CSF IL- 6 
levels; heterozygous variant of 
uncertain significance in RELN
Capizzi et al., 2015 Case report aFemale, 15 years Fever, asthenia, upper respiratory 
tract infection
Unknown
Caputo et al., 2017 Case report aFemale, 13 years Fever Encephalitis associated with 
GABAAR antibodies
Caraballo et al., 2013 Case series aN = 12, 
male:female 
= 8:4, mean 
age 8.5 (range 
2– 13.5) years
Fever and upper respiratory tract 
infection (9/12)
Fever and gastroenteritis (3/12)
Headache, drowsiness, confusion
Unknown









Chalhub et al., 1977 Case report Male, 3 months Upper respiratory tract infection, 
fever
Coxsackie A9 enteroviral infection
Chan et al., 2018 Case report Male, 31 years Fever, myalgia, upper respiratory 
symptoms, cough
Unknown
Cho et al., 2019 Case report Male, 76 years Acute confusional state Encephalitis associated with anti- 
SOX1 antibodies (history of 
stage IIIB squamous cell lung 
cancer)
Choi et al., 2019 Case series N = 13, male:female 
= 7:6, median 
age 45 





Upper respiratory tract infection 
symptoms (4/13)
Nausea/vomiting (3/13)
Acute memory impairment or 
confusion (12/13)
Unknown
Chou et al., 2016 Case report aFemale, 12 years Fever and upper respiratory tract 
infection
Unknown
Clarkson et al., 2019 Case control aN = 7, male:female 
= 5:2, age range 
1.5– 16 years
Febrile illness Elevated levels of IL- 1RA and IL- 1β 
in the serum and CSF
Functional deficiency in IL- 1RA 
inhibitory activity
Multiple variants within intronic 
sequences and a silent 
mutation in exon 6 of IL1RN
TA B L E  1  (Continued)
(Continues)
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Study Study design Population Prodromes Aetiology
Collaborative Group 
for Fever- induced 
Refractory Epileptic 
Encephalopathy in 
School- aged Children, 
2012
Case series cN = 13, 
male:female 
= 6:7, median 
age 8.3 years
Fever Unknown
Costello, 2009 Case series N = 6, male:female 
= 2:4, average 
age 28.5 (range 
24– 36) years
Fever and coryzal symptoms (i.e., 
nasal congestion, sore throat, 
myalgias) (4/6)
Persistent dry cough (2/6)
Unknown
Dahaba et al., 2010 Case report dFemale, 14 years Fever, upper respiratory tract 
infection
Unknown
Daida et al., 2020 Case report Female, 28 years Fever, disturbance of consciousness, 
automatisms, oral dyskinesia, 
upward- directed gaze palsy
Encephalitis associated with 
anti- ganglioside antibodies 
(IgG- GD1a, GT1b, GQ1b)
Dara et al., 2006 Case report Female, 31 years Newly diagnosed systemic lupus 
erythematosus (possible lupus 
cerebritis)
Deshmukh et al., 2019 
[86]
Case series N = 5, male:female 
= 4:1, age range 
56– 83 years
Carotid artery stenting
Dilena et al., 2019 [41] Case report aMale, 10 years Fever, upper respiratory tract 
infection
Unknown; serum testing for 
anti- basal ganglia antibodies 
showed the presence of 
antibodies against a still 
unidentified 150 kDa antigen
Dillien et al., 2016 [68] Case report Female, 27 years Flu- like syndrome Serum positivity for antibodies 
against Japanese encephalitis 
virus
Heterozygous single nucleotide 
variant in the sequence 
c.1280A>G [p.Lys427Arg] of 
SMC3
Donnelly et al., 2021 Case report Female, 26 years Unknown
Dono et al., 2020 Case report Male, 81 years Fever, mild dyspnoea, dry coughing Post SARS- CoV- 2 autoimmune 
encephalitis
Eaton et al., 2019 Case report Male, 19 years Nausea, headache Positivity for anti- GAD antibodies




Eguchi et al., 2019 Case report Male, 33 years Fever, fatigue Unknown
Farias- Moeller et al., 2017 Case series aN = 7, male:female 
= 4:3, mean age 
8 (range 5– 16) 
years
Non- specific febrile illness (upper 
respiratory tract infection with 
odynophagia or, less often, a 
gastrointestinal illness)
Unknown
Farias Moeller et al., 2018 
[33]
Case series aN = 5, male:female 
= 3:2, median 
age 4.5 (IQR 
4.5– 12.5), range 
4– 16 years
Non- specific febrile illness Unknown; secondary 
hemophagocytic 
lymphohistiocytosis in three 
cases
Fatuzzo et al., 2019 Case report aFemale, 29 years Febrile episode Unknown
Ferlisi et al., 2020 [69] Case report Female, 28 years; 





TA B L E  1  (Continued)
(Continues)
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Study Study design Population Prodromes Aetiology
Fisher et al., 2020 Case series aN = 8, mean age 
8.5 (range 4– 15) 
years
Febrile illness Unknown
Fox et al., 2017 Case report aFemale, 6 years Fever Unknown
Fukuyama et al., 2011 Case report dMale, 6 years Unknown
















Gaspard et al., 2015 [20] Case series N = 130, 
male:female 
= 47:83, age 
range 18– 81
Unknown (67/130)
Non- paraneoplastic autoimmune 
(25/130) (anti- NMDAR, 
anti- VGKC complex, steroid- 
responsive encephalopathy 
associated with autoimmune 
thyroiditis, cerebral lupus, anti- 
GAD, anti- striational)
Paraneoplastic (23/130) (anti- 
NMDAR, anti- VGKC complex, 
anti- Hu, anti- VGCC, anti- 
CRMP5, anti- Ro, seronegative)
Infection- related (10/130) (EBV, 
VZV, CMV, WNV, mycoplasma 
pneumoniae, syphilis, 
toxoplasma gondii)
Subacute encephalopathy with 




Creutzfeldt– Jakob disease (1/130)
Geva- Dayan et al., 2012 Case series aN = 9, age range 
2.5– 15
Febrile illness Unknown
Gofshteyn et al., 2017 Case series aN = 7, male:female 
= 5:2, average 
age 7 (range 
3– 8) years
Fever Unknown
Gonzalez- Martinez et al., 
2020
Case report Female, 82 years Altered consciousness, aphasia Creutzfeldt– Jakob disease
Goyal et al., 2020 Case report aMale, 13 months Fever Unknown
Gugger et al., 2019 Case series N = 20, 
male:female 
= 10:10, median 
age 50.5 (IQR 




Fever or infectious symptoms (9/20)
Headache (5/20)
Encephalopathy (12/20)
Autoimmune encephalitis (18/20) 
(anti- PCA- 2, voltage- gated 




Hainsworth et al., 2014 Case report Male, 24 years Encephalitis associated with 
anti- GABABR
Hamano et al., 2003 Case report dFemale, 5 years Unknown
Hau Man et al., 2017 Case report Male, 27 years Possible autoimmune encephalitis
TA B L E  1  (Continued)
(Continues)
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Study Study design Population Prodromes Aetiology
Helbig et al., 2020 Case series aN = 50, 
male:female 
= 33:17, median 
age 6 (range 
2– 15) years
Febrile illness Unknown
Hirayama et al., 2016 Case series dN = 2, male:female 
= 1:1, median 




Horino et al., 2021 Case control aN = 6, male:female 
= 5:1, mean age 
6 (range 4– 8) 
years
Febrile illness Unknown; increased CSF 
concentrations of CXCL10, 
CXCL9, IFN- γ, neopterin, IL- 1β, 
IL- 6 and IL- 8
Houk et al., 2019 Case report Male, 19 years Fever, malaise Unknown
Howell et al., 2012 Case series aN = 7, male:female 
= 7:0, median 
age 10.8 (range 
6.7– 14) years
Fever, headache, confusion and 
lethargy (7/7); upper respiratory 
tract symptoms and myalgias 
variably noted
Unknown
Hsieh et al., 2020 [40] Case control aN = 5, male:female 
= 4:1, age range 
(2– 13) years
Febrile illness Unknown; adenovirus and 
enterovirus in throat cultures 
(2/5)
Serum IgM of mycoplasma 
pneumoniae and HSV (2/5)
Impaired TLR3, TLR4, TLR7/8 and 
TLR9 responses in peripheral 
blood mononuclear cells and 
monocyte- derived dendritic 
cells
Hsu et al., 2020 Case control aN = 7, male:female 
= 5:2, age range 
4– 13 years
Fever Unknown
Hurth et al., 2019 Case report Female, 51 years Possible autoimmune encephalitis
Husari et al., 2020 [21] Case series N = 40, 
male:female 
= 21:19, median 
age 6.6 (IQR 
3.0– 10.4) years
Fever either at home or upon 
admission (30/40)
Fever only upon admission (12/40)
Fever prior to admission (27/40)





Psychiatric and behavioural 
symptoms (1/40)
Unknown (23/40)







Genetic (3/40) (DNM1L mutation, 
KCNT1 mutation, compound 
heterozygous POLG and 
cathepsin D mutations)
Husari et al., 2021 Case series Male, 75 years Confusion, cognitive decline Possible autoimmune encephalitis
Ibrahim et al., 2014 Case report Male, 21 years Influenza A (H1N1 infection)
Iizuka et al., 2017 [31] Case series N = 11, male:female 
= 4:7, median 
age 27 (range 
17– 59) years
Fever (10/11), headache (6/11) Unknown
Iizuka et al., 2019 Case series N = 24 Unknown
Iizuka et al., 2020 Case control N = 30, 
male:female 
= 13:17, median 
age 25 years
Unknown
TA B L E  1  (Continued)
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Study Study design Population Prodromes Aetiology
Illingworth et al., 2011 Case report dMale, 4 years Febrile illness Anti- VGKC complex antibodies
Ishikura et al., 2015 Case report Male, 23 years Antecedent infection Unknown; serum antibodies 
reacting against cytoplasm 
and nucleus in hippocampal 
neurons of rat brain section
Ismail et al., 2011 Case report aFemale, 14 years Fever, diarrhoea Unknown
Ito et al., 2005 Case report dMale, 11 years Fever Serum and CSF anti- Gluε2 
antibodies








De novo mutation of SCN10A
Unknown
Unknown
Jang et al., 2021 [27] Case series Male, 24 years Fever, headache Anti- myelin oligodendrocyte 
glycoprotein- associated 
disorder
Jayalakshmi et al., 2016 Case series N = 36 Unknown (33/36)
HSV encephalitis (3/36)
Jose et al., 2021 Case series N = 13 Fever (5/13) Autoimmune encephalitis (10/13)
Viral encephalitis (3/13)
Juhász et al., 2013 Case report Male, 56 years Headache Unknown





















Kaplan et al., 2017 Case report Female, 29 years Focal sensory- motor deficits, 
cognitive decline, emotional 
lability, intermittent confusion
Encephalitis associated with anti- 
NMDAR antibodies
Katz et al., 2021 Case report Female, 29 years Fever, headache, emesis, fatigue Unknown
Kaufman et al., 2017 Case report cFemale, 6 years Fever, strep throat Moyamoya angiopathy
Kenney- Jung et al., 2016 
[42]
Case report aFemale, 32 months Febrile respiratory infection Unknown
Kern Smith et al., 2020 Case report Male, 5 years Bartonella henselae infection
Khawaja et al., 2015 [84] Case series N = 11, male:female 
= 2:9, mean age 
48 (range 21– 
90) years
Autoimmune encephalitis (7/11) 
(anti- GAD, anti- NMDAR, anti- 
VGCC, anti- VGKC antibodies)
Unknown (3/11)
PRES (1/11)
Kikuchi et al., 2007 Case report dMale, 9 years Gastrointestinal infection Unknown
Kim et al., 2020 [90] Case series N = 39, male:female 
= 24:15, median 








History of traumatic subarachnoid 
haemorrhage (1/39)
Kobayashi et al., 2010 [61] Case series dN = 7, male:female 
= 5:2, age range 
5– 8 years
Common cold (4/7), fever (2/7), 
acute enterocolitis (1/7)
Unknown; SCN1A- R1575C 
mutation (1/7)
TA B L E  1  (Continued)
(Continues)
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Study Study design Population Prodromes Aetiology
Kobayashi et al., 2012 [62] Case series dN = 8 Fever and cold- like symptoms Unknown; missense mutation 
c.3383T>C (Met1128Thr) in 
SCN2A (1/8)
Kodama et al., 2018 Case report Male, 31 years Fever Unknown
Kothur et al., 2019 [37] Case control aN = 4 Febrile illness Unknown; increased CSF levels 
of Th1- associated cytokines/
chemokines (TNF- α, CXCL9, 
CXCL10, CXCL11), IL- 6, CCL2, 
CCL19 and CXCL1
Kramer et al., 2005 [14] Case series N = 8, age range 
2.5– 15 years
Fever (7/8), erythematous rash (1/8) Unknown
Kramer et al., 2011 Case series N = 77, male:female 
= 4:3, median 
age 8 (range 
2– 17) years
Fever (74/77), upper respiratory 
tract infection (30/77), 
gastroenteritis (15/77), otitis 
media (2/77), mastoiditis (1/77), 
pneumonia (1/77), herpes 
labialis (1/77), rash (1/77)
Unknown; anti- GAD antibodies in 
two of five tested patients, and 
anti- GluR3 antibodies in one of 
four tested patients
Kumari et al., 2015 Case report Male, 31 years Generally feeling unwell and weight 
loss
Neurosyphilis
Kurukumbi et al., 2019 Case report Male, 25 years Upper respiratory tract infection Unknown
Kwan et al., 2020 Case report Male, 67 years Encephalitis associated with 
GABABR antibodies (in small 
cell prostate cancer)
Lai et al., 2020 Case series aN = 25, 
male:female 
= 16:9, median 
age 8 (range 
5– 16) years
Febrile illness Unknown; increased CSF 
cytokines (3/10)
Increased CSF neopterin (3/10)
Increased serum cytokines (8/9)
Increased serum neopterin (3/9)
Lam et al., 2019 Case series aN = 20, 
male:female 
= 12:8, mean 
age 9.6 ± 4.4 
(range 1.6– 17.2) 
years
Upper respiratory tract infection 
(14/20), fever with unknown 
focus (4/20), gastrointestinal 
tract symptoms (2/20)
Unknown
Laswell et al., 2015 Case report Female, 28 years Bartonella henselae infection
Lee et al., 2018 Case series aN = 29, 
male:female 
= 12:17, median 
age 8.9 (range 
1.2– 17.8) years
Fever (27/29), upper respiratory 
tract infection (21/29), nausea/
vomiting/diarrhoea (10/29)
Unknown









Lin et al., 2009 Case series dN = 9, male:female 
= 7:2, age range 
5– 15 years
Fever (9/9), upper respiratory 
tract infection (6/9), headache 
(4/9), vomiting (3/9), altered 
consciousness (2/9), sore throat 
(1/9)
Unknown
Lin et al., 2012 Case series aMale, 10 years
aFemale, 4 years
Fever, flu- like symptoms
Febrile illness
Unknown






Maloney et al., 2020 Case report Male, 19 years Anti- GAD antibodies
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Manganotti et al., 2021 
[50]
Case series Male, 37 years
Male, 71 years
Respiratory failure symptoms Post SARS- CoV- 2 autoimmune 
encephalitis
Post SARS- CoV- 2 autoimmune 
encephalitis
Marashly et al., 2017 [91] Case report Female, 3 years Focal cortical dysplasia type II
Matar et al., 2017 [85] Case report Male, 46 years Headache, wide- based gait, 
unsteadiness
Primary angiitis of the central 
nervous system
Matsuzono et al., 2014 Case report dMale, 22 years Fever, headache Unknown
Matthews et al., 2020 [28] Case series N = 26, male:female 
= 8:18, age 
peaks at 27 and 
63 years
Fever (13/26), fatigue/malaise 
(17/26), headache (11/26), 
myalgias (3/26), upper 
respiratory infection (6/26), 
diarrhoea (2/26), nausea/
vomiting (8/26), rash (5/26), 
agitation (2/26), paranoia 
(3/26), hallucinations (4/26), 
insomnia (2/26), mutism (1/26), 
uncontrollable laughter (1/26)
Unknown (19/26)





Mazzuca et al. 2011 Case series aN = 8, male:female 









Meletti et al., 2017 Case series N = 31, male:female 
= 14:17, mean 
age 24.6 ± 
12.4 years
Fever with flu/cold symptoms/
general malaise (28/28)
Altered mental status (22/31)
Unknown
Mikaeloff et al., 2006 [15] Case series eN = 14, 
male:female 
= 7:7, median 
age 7.5 (range 
4– 11) years
Febrile illness (mainly upper 
respiratory tract infection, with 
or without rash)
Unknown
Milh et al., 2011 Case report aMale, 5 years Fever, upper respiratory tract 
infection
Serum and CSF anti- neuropil 
antibodies
Miràs Veiga et al., 2017 Case report aMale, 4 years Fever, pharyngitis Unknown
Mizutani et al., 2019 Case report Male, 30 years Fever, diarrhoea, headache Unknown
Moise et al., 2019 Case series N = 12 Encephalitis associated with anti- 
NMDAR antibodies (N = 4)
Encephalitis associated with anti- 
VGKC antibodies (N = 1)
Encephalitis associated with anti- 
GAD antibodies (N = 3)
Probable autoimmune encephalitis 
(N = 4)
Monti et al., 2020 [51] Case report Male, 50 years Fever, psychiatric symptoms 
(confabulations and delirious 
ideas)
Encephalitis associated with 
anti- NMDAR antibodies; 
asymptomatic SARS- CoV- 2 
infection
Morrison et al., 2020 [57] Case report Female, 23 years Mutation in POLG
Myers et al., 2017 Case report Male, 23 months Fever Unknown
Nair et al., 2014 Case report Female, 24 years Headache, fever Unknown
Nardetto et al., 2017 Case report Female, 19 years Fever, laterocervical 
lymphadenopathy
Unknown
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Neuwirth et al., 2008 Case series dN = 5, median 
age 11.5 (8– 14) 
years
Unknown
Newey et al., 2019 Case series Male, 28 years Upper respiratory viral illness Unknown; serum anti- thyroid 
peroxidase and anti- 
thyroglobulin antibodies
Nolan et al., 2014 Case report Male, 20 years Encephalitis associated with anti- 
NMDAR antibodies
Nozaki et al., 2013 Case report cMale, 7 years Fever associated with tonsillitis Unknown
Ogawa et al., 2016 Case report dMale, 11 years Fever Unknown
Okanishi et al., 2007 Case report dMale, 14 years Fever, headache, vomiting, eruption Serum anti- Gluε2 antibodies
Patel et al., 2017 [82] Case report Male, 19 years History of synthetic cannabinoid- 
associated seizures
Abuse of synthetic cannabinoids
Patil et al., 2016 Case series cN = 15, 
male:female 
= 12/3, median 
age 6.3 (range 
3– 15) years
Non- specific respiratory infection 
(12/15), acute diarrhoeal disease 
(2/15), fever with non- specific 
lymphadenopathy (1/15)
Unknown
Peng et al., 2019 Case series aN = 7, male:female 
= 4:3, median 
age 8 (range 
1.5– 13) years
Fever of unknown origin (3/7), 
upper respiratory tract infection 
(3/7), gastroenteritis (1/7)
Unknown
Petit- Pedrol et al., 2014 
[23]
Case control N = 6, male:female 
= 5:1, median 
age 22 (range 
3– 63) years
Memory, cognitive and affective 
problems, behavioural changes, 
choreoathetoid movements
Encephalitis associated with 
GABAAR antibodies
Puoti et al., 2013 Case report Male, 41 years Fever, vomiting Unknown
Rivas- Coppola et al., 2016 Case series aN = 7, male:female 
= 6:1, median 
age 4.7 years 
(range 3 months 
to 9 years)
Non- specific febrile illness (upper 
respiratory tract infection, 
gastroenteritis)
Unknown
Rochtus et al., 2020 Case series cN = 5, male:female 
= 3:2, age range 
7– 14 years
Fever Unknown
Sa et al., 2019 Case series aMale, 9 years
aMale, 5 years
Fever, vomiting, headache
Fever, abdominal pain, coryza
Unknown (increased CSF 
neopterin levels)
Unknown









Late positivity of serum GluRε2 
antibodies
Unknown
Saitoh et al., 2016 [65] Case control cN = 19 Fever Unknown; association with IL1RN 
haplotype containing RN2; 
possible association of IL1RN 
rs4251981G>A and SCN2A 
rs1864885A>G
Sakuma et al., 2001 Case series dN = 22 Unknown
Sakuma et al., 2010 [16] Case series dN = 29, 
male:female 
= 19:10, mean 
age 6.8 ± 4.0 
(range 1– 14) 
years
Febrile illness (29/29) Unknown; serum (6/9) and CSF 
(5/9) anti- GluRε2 antibodies; 
increased CSF neopterin (4/4)
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Sakuma et al., 2015 [36] Case control dN = 14 Fever Unknown
Increased serum and CSF levels 
of proinflammatory cytokines 
(such as IL- 6, macrophage 
migration inhibitory factor) and 
chemokines (such as CXCL10, 
IL- 8); T- cell- associated 
cytokines (such as IL- 2, IL- 17A) 
and homeostatic chemokines 
(such as CCL21, CXCL12) 
unchanged or downregulated





Progressive memory, language and 
writing impairment, auditive 
illusions
Subacute confusional state, 
behaviour disorder, auditive 
illusions
Memory impairment, fatigue, 
weight loss, confusion
Headache, visual illusions, language 
impairment
Apathy, anorexia, weight loss, 
aphasia, hypersomnolence
Paraneoplastic autoimmune 
encephalitis associated with 
anti- Hu antibodies (in small cell 
lung carcinoma)
Seronegative autoimmune 
encephalitis (in mixed small 
cell lung carcinoma and 
adenocarcinoma)
Paraneoplastic autoimmune 
encephalitis associated with 
anti- Hu antibodies (in small cell 
lung carcinoma)
Seronegative autoimmune 
encephalitis (in colorectal 
adenocarcinoma)
Seronegative autoimmune 
encephalitis (in lung 
adenocarcinoma)
Sato et al., 2016 Case report dMale, 11 years Fever CSF anti- GluRε2 antibodies; 
increased CSF cytokine levels 
(TNF- α), IL- 6, IL- 10, IFN- γ
Savard et al., 2018 Case report Male, 31 years Headache, fever, myalgia Encephalitis associated with 
Jamestown Canyon virus 
infection
Schoeler et al., 2021 Case series aN = 8, male:female 
= 6:2, mean age 
7.9 ± 1.7 (range 
5.8– 10.8) years
Febrile illness Unknown
Seniaray et al., 2020 Case report Male, 14 years Fever Unknown
Serrano- Castro et al., 
2013
Case report cFemale, 19 years Fever, myalgia, malaise Unknown
Sharma et al., 2013 Case report Male, 30 years Fever Unknown
Shibata et al., 2019 Case control dN = 18, 
male:female 
= 15:3, mean 
age 81.4 ± 35.4
Febrile illness Unknown
Shiraga et al., 2010 Case report dMale, 5 years Fever Unknown
Shrivastava et al., 2017 Case report Female, 24 years Unknown
Shukla et al., 2018 Case series aN = 5, male:female 
= 4:1, median 
age 7 (range 
4– 15) years
Febrile illness Unknown
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Shyu et al., 2008 Case series dN = 14, 
male:female 
= 7:7, age range 
1– 15 years
Fever (13/14), upper respiratory 
tract infection symptoms 
(12/14), gastrointestinal tract 
discomfort (6/14)
Unknown
Singh et al., 2014 Case series aMale, 7 years
aFemale, 10 years
Fever, headache, malaise, papular 
rash, erythematous oropharynx




Singhal et al., 2003 Case series Female, 27 years
Female, 66 years
Confusion Bartonella henselae infection
Bartonella henselae infection
Specchio et al., 2010 Case series cN = 8, mean age 
7.4 ± 5.9 years
Fever Unknown; positivity of anti- GAD 
antibodies (2/8)
Specchio et al., 2011 Case report cFemale, 8 months Febrile gastroenteritis Missense mutation (c.1129G>C; 
p.Asp377His) in PCDH19
Steriade et al., 2018 Case control N = 5, male:female 
= 1:4, mean age 
57 (range 26– 
83) years
Encephalitis associated with anti- 
VGKC and LGI1 antibodies 
(3/5), encephalitis associated 
with GABABR antibodies (1/5), 
seronegative autoimmune 
encephalitis (1/5)
Stredny et al., 2020 Case report aMale, 6 years Febrile illness Unknown
Strohm et al., 2019 Case series N = 12, 
male:female 
= 10:2, mean 
age 40 (range 
14– 78) years
Viral prodrome (7/12) Encephalitis associated with 
anti- NMDAR antibodies 
(4/12), anti- GAD antibodies 
(3/12), anti- LGI1 antibodies 
(1/12), anti- GABABR receptor 
antibodies (1/3), anti- VGKC 
complex antibodies (1/12)
Suleiman et al, 2013 Case series cMale, 3 years
cFemale, 8 years




Tan et al., 2018 Case report aFemale, 8 years Fever, headache Unknown
Theroux et al., 2020 Case report aMale, 11 years Fever HHV- 6 encephalitis; a single 
variant of uncertain 
significance in PLCB1
Trandafir et al., 2020 Case report Female, 21 years Fever Unknown
Tsubouchi et al., 2017 Case series dFemale, 
101 months
Unknown
Uchida et al., 2016 Case report dMale, 9 years Vomiting, diarrhoea, drowsiness CSF anti- GluRε2- NT and anti- 
GluRε2- CT1 antibodies
Increased CSF neopterin levels
Ueda et al., 2015 Case series dN = 6, male:female 
= 4:2, age range 
7– 10 years
Febrile illness Unknown
Ungureanu et al., 2018 Case report Male, 62 years Fever Unknown
Vaccarezza et al., 2012 Case series aN = 3 Fever Unknown
Vallecoccia et al, 2020 Case report Male, 34 years Fever, headache Unknown
van Baalen et al., 2010 
[17]
Case series cN = 22, 
male:female 
= 16:6, median 
age 6.5 (range 
3– 15) years
Respiratory tract infection (11/22), 
non- specific febrile infection 
(6/22), headache (2/22), otitis 
media (1/22), mastoiditis (1/22), 
herpes labialis (1/22)
Unknown; serum anti- GluR- 3 
antibodies (1/22)
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van Baalen et al., 2012 Case series cN = 12, 
male:female 
= 6:6; median 
age 6 (range 
2– 12) years
Respiratory tract infection (8/12), 
parvovirus B19 infection (1/12), 
lethargy (1/12), enteritis (1/12), 
vomiting and headache (1/12)
Unknown
Van Lierde et al., 2003 Case series N = 6, male:female 
= 2:4, median 
age 23 (range 
18– 30) years
Febrile illness Unknown
Varrasi et al., 2017 [29] Case report Male, 48 years Hashimoto's encephalopathy
Verma et al., 2013 Case report Female, 35 years Fever, cough HSV encephalitis
Villamar et al., 2020 Case report Female, 15 years Listlessness and decline in academic 
performance
Rabies encephalitis




von Spiczak et al., 2017 
[60]
Case series aFemale, 4.5 years Febrile illness DNM1 mutation (c.1117G>A; 
p.Glu373Lys)
Waheed et al., 2014 [80] Case report Female, 27 years Drowsiness; bradycardia, 
bronchorrhoea, drooling of 
saliva, pinpoint pupils
Organophosphate poisoning
Wakamoto et al., 2012 Case report dMale, 7 years Fever and cough Unknown
Serum and CSF antibodies against 
GluRε2, ζ1 and δ2 subunits
Increased serum levels of IL- 2, 
IL- 6, IL- 10, TNF- α and IFN- γ; 
increased CSF levels of IL- 6
Decreased natural killer cell 
activity in peripheral blood 
mononuclear cells
Wang D et al., 2020 Case series N = 18, male:female 
= 6:12, median 
age 23.5 (range 
17– 76) years
Unknown (8/18 with positive 
serum immunostaining and 
4/18 with positive serum and 
CSF immunostaining of rat 
hippocampus section were 
considered to have antibodies 
against hippocampus 
neuropils)
Wang X et al., 2020 Case series aN = 10, 
male:female = 
4:6, median age 
9 (range 5– 13) 
years
Fever Unknown
Watanabe et al., 2014 Case report dMale, 8 years Unknown
Westbrook et al., 2019 
[43]
Case report aFemale, 21 years Intermittent fever, headache Unknown; serum positivity for 
CASPR2 antibodies and 
weak positivity for anti- GAD 
antibodies after 5 days of 
intravenous immunoglobulin 
administration
Wilder- Smith et al., 2005 Case series N = 7 Fever (2/7), fever and headache 
(2/7), fever and diarrhoea (1/7)
Unknown
Wu et al., 2020 [87] Case report Female, 46 years Unknown (history of multiple 
blood transfusions)
Yamamoto et al., 2014 Case report Male, 35 years Febrile upper respiratory illness Unknown
Yamashita et al., 2001 Case report Male, 29 years Flu- like symptoms Unknown
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Yamazoe et al., 2017 Case report Male, 24 years Fever, upper respiratory 
infection, delirium, shouting of 
meaningless words
Encephalitis associated with anti- 
GluR antibodies
Yanagida et al., 2020 [30] Case series N = 33 Unknown
Zhang et al., 2016 Case report dMale, 46 years Fever, headache Unknown
Note: Studies (n = 197) are sorted in alphabetical order.
Patients presented with afebrile infection- related epilepsy syndrome, bidiopathic catastrophic epileptic encephalopathy presenting with acute onset 
intractable status, cfever induced refractory epileptic encephalopathy in school- aged children, dacute encephalitis with refractory, repetitive partial 
seizures and edevastating epileptic encephalopathy in school- aged children.
Farias- Moeller et al. (2018) included patients previously described in Farias- Moeller et al. (2017). Kramer et al. (2011) included patients previously 
described in Baxter et al. (2003), Kramer et al. (2005), Mikaeloff et al. (2006), Shyu et al. (2008), Specchio et al. (2010) and van Baalen et al. (2010). 
Lee et al. (2018) included patients previously published in Saito et al. (2007). Peng et al. (2019) included patients previously published in Howell et al. 
(2012) and Kramer et al. (2011). Yanagida et al. (2020) included patients previously described in Iizuka et al. (2019).
Abbreviations: ADEM, acute disseminated encephalomyelitis; CACNA1A, calcium voltage- gated channel subunit alpha 1A; CASPR2, contactin- 
associated protein- like 2; CMV, cytomegalovirus; CRMP5, collapsing response mediator protein 5; CSF, cerebrospinal fluid; DNM1L, dynamin 1- like 
protein; EBV, Epstein– Barr virus; GABAAR, γ- aminobutyric acid A receptor; GABABR, γ- aminobutyric acid B receptor; GAD, glutamate decarboxylase; 
GluR, glutamate receptor; HHV- 6, human herpesvirus 6; IFN, interferon; Ig, immunoglobulin; IL, interleukin; IL- 1RA, IL- 1 receptor antagonist; IQR, 
interquartile range; KCNT1, potassium sodium- activated channel subfamily T member 1; LGI1, leucine- rich glioma- inactivated 1; NMDAR, N- 
methyl- d- aspartate receptor; PCA- 2, Purkinje cell cytoplasmic antibody type 2; PCDH19, protocadherin 19; PLCB1, phospholipase C β1 gene; POLG, 
DNA polymerase subunit G; PRES, posterior reversible encephalopathy syndrome; RELN, reelin; SARS- Cov- 2, severe acute respiratory syndrome 
coronavirus 2; SCN2A, sodium voltage- gated channel alpha subunit 2; SCN10A, sodium voltage- gated channel alpha subunit 10; SMC3, structural 
maintenance of chromosomes 3; SOX1, SRY- box transcription factor 1; TLR, toll- like receptor; TNF- α, tumour necrosis factor α; TPO, tireoperoxidase; 
VGCC, voltage- gated calcium channel; VGKC, voltage- gated potassium channel; VZV, varicella zoster virus; WNV, West Nile virus.
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the mechanisms of seizure generation are not fully understood, anti- 
NMDAR antibodies can induce the internalization of the receptors, 
antibodies anti- LGI1 can promote the disruption of synaptic protein 
localization, and antibodies against GABABR can act as neurotrans-
mitter antagonists [22]. The GABAAR has been identified more 
recently as a target of autoimmune, usually non- paraneoplastic, en-
cephalitis and associated with NORSE both in children and in adults 
[23,24]. Interestingly, GABAAR antibodies cause a selective decrease 
of the clusters of GABAAR at synaptic sites, without altering other 
post- synaptic proteins such as the NMDAR or gephyrin; further, the 
total density of GABAARs including synaptic and extra- synaptic re-
ceptors is not affected, suggesting a relocation of receptors from 
synaptic to extra- synaptic sites [23]. Antibodies against glutamate 
decarboxylase and classic onconeural antibodies targeting intra-
cellular neural antigens, including antibodies against collapsing re-
sponse mediator protein 5, Hu, Yo, Ri, Ma2, SRY- box transcription 
factor 1 (SOX1) and amphiphysin, are variably associated with dif-
ferent types of tumours.
In contrast to antibodies directed against neuronal cell surface 
antigens, onconeural antibodies are thought to mainly represent the 
epiphenomenon of the underlying immune cascade in which cellular 
immunity can play the dominant role, mainly through cytotoxic T cell 
infiltration and granzyme B- mediated damage [22,25].
Cases of NORSE have also been reported in association with 
other autoimmune disorders, including autoimmune encepha-
lopathy with elevated anti- thyroid antibodies, for example anti- 
thyroid peroxidase, myelin oligodendrocyte glycoprotein (MOG) 
antibody- associated disease, acute disseminated encephalomyelitis, 
and encephalitis associated with systemic lupus erythematosus 
[20,21,26– 30].
Distinguishing NORSE secondary to autoimmune encephalitis 
from c- NORSE is important as treatment and prognosis may differ 
[31]. In clinical practice, however, excluding the possibility of c- 
NORSE may be challenging, mainly at the early stage of SE before 
the results of antibody testing become available [30]. In this regard, 
the c- NORSE score is a clinically based scoring system that has been 
developed to early predict c- NORSE and includes the following fea-
tures: presence of prodromal high fever of unknown origin before 
the onset of SE, absence of prodromal psycho- behavioural or mem-
ory alterations before SE onset, absence of sustained orofacial- limb 
dyskinesias despite a profoundly decreased level of consciousness, 
and symmetric brain magnetic resonance imaging abnormalities 
[30]. Patients with a high score are more likely to be negative for 
neuronal antibodies, have c- NORSE, be less responsive to first- line 
immunotherapy and have poor outcome [30].
Interestingly, the presence of neuronal antibodies is rare in 
cases of FIRES, but testing in this population is often incomplete 
[21,22], and the underlying aetiology cannot be identified in most 
patients. Cases of FIRES also appear to have less inflammatory 
cellular infiltrate and be less responsive to first- line immunother-
apies than NORSE associated with autoimmune encephalitis [22]. 
Autoantibodies may not have a relevant contribution to c- NORSE 
and FIRES, and innate immune pathways may play a more important 
role than adaptive immunity [31]. Inflammation- mediated epilepto-
genesis has been proposed [32], and a vicious cycle involving inflam-
mation and seizure activity is assumed to promote cell death and 
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network reorganization, ultimately leading to refractory seizures. An 
imbalance between pro- and anti- inflammatory mediators, possibly 
following a febrile or infectious illness, can activate innate immune 
pathways in glial cells, neurons, astrocytes and cellular components 
of the blood– brain barrier resulting in an uncontrolled neuroinflam-
matory cascade [33]. The release of cytokines, chemokines and adhe-
sion molecules promotes infiltration of peripheral immune effectors. 
The inflammatory milieu contributes to developing a hyperexcitable 
state via phosphorylation of NMDAR, change in ion channels, al-
tering glutamate and GABA release and reuptake, modification of 
GABA receptor trafficking and deficient buffering of astrocytes [33]. 
Concerning chemokines, CCL2 has an important role in promoting 
the production of interleukin- 1β (IL- 1β), causing neuronal cell death 
and altering calcium signalling, whilst CX3CL1 negatively influences 
GABA- ergic activity [34]. Prolonged exposure to neuroinflamma-
tion induces long- term transcriptional changes leading to changes 
in neurogenesis, sprouting and angiogenesis, and contributing to 
increased epileptogenesis [35]. In turn, seizure activity triggers neu-
roinflammation perpetuating a cycle of innate immune activation. Of 
note, the presence of brain inflammation in c- NORSE and FIRES is 
strongly suggested by either the antecedent febrile infectious dis-
eases or laboratory findings. Proinflammatory cytokines such as IL- 
1β and IL- 6 have received attention as potential key molecules in 
c- NORSE, and high levels of IL- 6 and chemokines like CXCL10 and 
IL- 8 have been found in serum and cerebrospinal fluid (CSF) in pae-
diatric cases of FIRES with an immune signature markedly different 
from that associated with encephalitis [36,37]. The higher levels of 
inflammatory cytokines and interleukins found in FIRES compared to 
afebrile SE or refractory epilepsies with high frequency of seizures 
support the presence of neuroinflammation and its relationship with 
disease pathogenesis rather than simply being the effect of seizure 
activity [37,38]. The reported co- occurrence of FIRES and secondary 
hemophagocytic lymphocytic histiocytosis, a rare hyperinflamma-
tory haematological syndrome characterized by cytokine storm [39], 
further reinforces the possibility of an immune dysregulation pheno-
type serving as one mechanism underlying acute epileptogenesis. It 
is noteworthy that around one- fifth of patients with c- NORSE had a 
past medical history of febrile convulsions, a family history of febrile 
convulsion or both [30]: it is arguable that a genomic susceptibility 
may exist, and a genetic predisposition may contribute to the devel-
opment of these conditions following fever illness in a small group 
of subjects. Impairment of toll- like receptor pathways with weak-
ened phagosome- associated responses and decreased T naïve and 
regulatory cells have been observed in children with FIRES [40]. As 
well as the lower number of naïve T cells can increase susceptibility 
to viral infections, weakened phagocytosis cannot allow the timely 
eradication of pathogens, mainly viruses, and result in the accumu-
lation of damaged debris. By mimicry mechanisms, damaged debris 
can behave as epitopes cross- reactive with neural components and 
induce autoimmunity. The reduction in T regulatory cells can further 
result in inadequate suppression to counteract unwanted autoim-
mune and inflammation responses [40]. The potential pathogenetic 
role of immune mechanisms is further sustained by the evidence, 
despite limited to a few case reports, of successful response to anti- 
cytokine therapies like anakinra [41– 43], an IL- 1 receptor antagonist, 
and tocilizumab, an IL- 6 receptor antagonist [44], in patients refrac-
tory to steroids, intravenous immunoglobulins, plasma exchange and 
second- line therapies such as rituximab.
The limits to using antibodies as biomarkers of autoimmune pro-
cesses need to be acknowledged. Indeed, not all autoimmune dis-
eases are mediated by antibodies, not all antibodies are known, and 
detecting antibodies, mainly in serum, does not necessarily prove 
a causative relationship. As antibodies represent the downstream 
products of the immune activation, biomarkers of upstream immune 
alterations may be more reliable to detect and monitor autoimmune- 
related conditions [17]. Cytokine and inflammatory molecular panels 
in serum and CSF are being considered and may represent promising 
candidates for diagnosis and prognosis in NORSE and FIRES [22].
Infectious- related encephalitis can cause NORSE. A variety of 
pathogenic organisms can be responsible, viruses being the most im-
plicated, and may depend on the agents that are endemic in each re-
gion. Infections are the prevalent aetiology of paediatric NORSE and 
represent around 20% of cases [21], whereas they are the causes in 
only around 10% of adult patients [45]. Infectious causes should be 
sought early as delays in starting treatment may worsen prognosis, 
as in encephalitis due to herpes simplex virus (HSV), and the identi-
fication of the responsible agent can guide targeted therapies [45]. 
In this regard, clinical metagenomic next- generation sequencing of 
CSF or brain tissue represents a promising tool to investigate the 
various aetiologies of central nervous system (CNS) infections [46]. 
It allows for identification and genomic characterization of a com-
prehensive spectrum of potential causes including bacteria, fungi, 
parasites and viruses in a single test and without need for prior 
knowledge of a specific pathogen [47]. This technique may be help-
ful in identifying the pathogen, especially when other more directed 
assays such as polymerase chain reaction fail [48], or excluding an 
infectious aetiology.
Recently, cases of NORSE have been reported in patients with 
severe acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) in-
fection, either asymptomatic or symptomatic [49– 51]. Therapeutic 
approaches included the administration of intravenous immuno-
globulin and plasma exchange, which resulted in the complete reso-
lution of seizures; anti- NMDAR antibody positivity and raised levels 
of IL- 6 and IL- 8 in CSF were found in one patient [51]. Although a 
definite pathogenetic role cannot be proved, the reported cases sug-
gest that SARS- CoV- 2 infection could trigger autoimmune responses 
with CNS involvement. Some patients with autoimmune encephali-
tis associated with coronavirus disease 2019 (COVID- 19) have been 
reported, in which behavioural disturbances, confusion, drowsiness 
and new- onset epilepsy represented the main symptoms at onset 
[52,53]. Furthermore, anti- NMDAR encephalitis can be triggered by 
viral infection, as reported after the infection by HSV [54]. The sec-
ondary hyper- inflammation syndrome and ‘cytokine storm’ associ-
ated with COVID- 19 may also play a role in promoting and sustaining 
refractory or super- refractory SE [55]. Of note, IL- 6 is raised during 
the inflammatory phase of COVID- 19, and increased CSF levels of 
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IL- 6 have been shown to facilitate intrathecal synthesis of autoanti-
bodies in anti- NMDAR encephalitis [56].
Genetic and congenital disorders can also have a causative role 
in NORSE. Mitochondrial disorders associated with mutations of the 
genes encoding the presynaptic dynamin 1- like protein (DNM1L) 
and the catalytic subunit of mitochondrial DNA polymerase gamma 
(POLG1) have been diagnosed in patients presenting NORSE [21,57– 
60]. Of note, valproic acid should preferentially be avoided in these 
cases due to the risk of inducing hepatic failure, and propofol and thio-
pental have also been suggested to potentially lead to the develop-
ment of hepatocellular dysfunction [58]. Importantly, the absence of 
the typical abnormalities observed in mitochondrial diseases does not 
exclude the diagnosis. Indeed, normal serum and CSF lactate, normal 
very long chain fatty acids, and muscle biopsy revealing normal histol-
ogy and normal mitochondrial respiratory chain enzyme analysis have 
been found within the spectrum of DNM1L variants [58].
Mutations of genes encoding neuronal channels, including differ-
ent types of voltage- gated sodium channel alpha subunits (SCN1A, 
SCN2A, SCN10A) [61– 63], potassium sodium- activated channel 
subfamily T member 1 (KCNT1) [21], calcium voltage- gated channel 
subunit alpha1 (CACNA1A) [64] and mutation in cathepsin D [21] 
have been detected in cases of NORSE. In addition, FIRES in female 
patients during infancy and early childhood can be one of the possi-
ble phenotypes of mutations in protocadherin 19 gene.
Cytokine- related polymorphism, namely the IL- 1 receptor antag-
onist (IL1RN) haplotype containing RN2 allele, has been associated 
with FIRES in Japanese patients [65]. The IL1RN encodes the IL- 1 
receptor antagonist (IL- 1RA), a member of the IL- 1 cytokine family 
that binds non- productively to the cell surface interleukin- 1 recep-
tor (IL- 1R) preventing IL- 1 from sending the signal to the cell. The 
IL- 1RA inhibits the activities of IL- 1α and IL- 1β and modulates a va-
riety of IL- 1- related immune and inflammatory responses during the 
acute phase of infection and inflammation. The presence of RN2 
results in reduced IL1RN expression and enhanced IL- 1β production 
[66,67] and may confer susceptibility to excessive inflammatory re-
sponse. This evidence is further support for the growing evidence of 
the implication of neuroinflammation in NORSE and NORSE- related 
conditions. Although the association between IL1RN polymorphism 
and the susceptibility to specific infections with a predilection to 
CNS complications cannot be excluded, it is worth noticing that 
symptoms of febrile illnesses preceding FIRES are non- specific and 
pathogens remain unidentified in most cases [65]. An inherited het-
erozygous single nucleotide variant in the structural maintenance of 
chromosomes protein 3 (SMC3) gene was identified in a patient with 
NORSE [68]. Whilst mutations in the SMC3 have been associated 
with the Cornelia de Lange syndrome type 3, the patient did not 
have the typical expressive phenotype, and the clinical significance 
remains unknown. A case of prolonged NORSE with no evidence of 
autoimmune activation and a good neurological recovery was de-
scribed in a patient with a mild form of Axenfeld– Rieger syndrome 
[69]. This is a rare genetic disorder characterized by dysgenesis of 
the anterior segment of the eye, craniofacial dysmorphism, den-
tal, cardiac and umbilical anomalies, and generally associated with 
mutations and deletions in the FOXC1 and PITX2 genes [70]. Genetic 
analysis in this patient was declined, however, and a causal associa-
tion could not be proved. Recently, a heterozygous variant in RELN 
was found in a case of FIRES responsive to plasmapheresis and to-
cilizumab [71]. The gene encodes reelin, a secreted glycoprotein 
that is produced by specific cell types within the developing brain 
and activates a signalling pathway in post- mitotic migrating neurons 
required for proper positioning of neurons within nervous system 
parenchyma [72]. Mutations in RELN have already been associated 
with lissencephaly and familial temporal lobe epilepsy 7 [73,74]; the 
causative significance in FIRES remains to be further explored.
Genetic technologies have the potential to enhance our under-
standing of the causes and mechanisms of NORSE. So far, genetic 
testing is still underperformed, and its role is worth improving. 
Furthermore, rapid whole exome sequencing may be advanta-
geous over a stepwise approach based on epilepsy panels and the 
relevance of this technique in the critical care setting will certainly 
improve as it becomes more readily available and affordable [75]. 
Alcohol has been associated with the development of NORSE within 
the context of subacute encephalopathy with seizures in alcoholic 
patients (SESA) [20]. First described in 1981 [76,77], SESA syn-
drome occurs in chronic alcoholism, is quite distinct from patients 
presenting with typical alcohol withdrawal seizures, and is charac-
terized by focal nonconvulsive SE, lateralized periodic discharges on 
the electroencephalogram, encephalopathy, chronic microvascular 
ischaemia on neuroimaging studies, and possible recurrence when 
chronic antiseizure treatment is stopped [78]. Cases of NORSE have 
also been reported after exposure to toxic substances, including 
organophosphate compounds that are pesticides extensively used 
in agriculture [79,80] and synthetic cannabinoids [81,82]. Delta- 9- 
tetrahydrocannabinol (THC) is the major constituent of marijuana 
and decreases GABA synaptic transmission by acting at the canna-
binoid receptor type 1 (CB- 1). As most of the synthetic cannabinoids 
are full agonists at CB- 1, they can produce a more profound GABA 
inhibition and be associated with an increased risk of epileptic activ-
ity compared with natural compounds, as THC is only a partial CB- 1 
agonist [83].
Less commonly reported causes of NORSE include disorders of 
vascular origin, such as posterior reversible leukoencephalopathy 
[84] and primary angiitis of the CNS [85]; carotid artery stenting has 
also been hypothesized to be associated with NORSE through cere-
bral hyper- perfusion syndrome [86].
New- onset refractory status epilepticus following multiple blood 
transfusions in a patient with severe anaemia secondary to men-
orrhagia was recently reported [87]; speculative mechanisms may 
include the rise in blood viscosity and sudden reversal of compen-
satory vasodilation, which result in endothelial damage, vasogenic 
oedema and parenchymal irritation [88]. Paradoxical worsening of 
oxygen delivery secondary to red blood cell storage lesions could 
also occur [89], although the effects on the CNS have not been 
described. Structural defects, like polymicrogyria [90] and focal 
cortical dysplasia [91], and rare conditions such as primary leptome-
ningeal melanomatosis, an exceedingly uncommon manifestation of 
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melanoma [92], and Creutzfeldt– Jakob disease have also been de-
scribed in association with NORSE presentation [20,93]. This review 
summarizes the available evidence about the aetiologies of NORSE 
and NORSE- related conditions, provides critical insights into the un-
derlying pathophysiology and suggests implications for clinical prac-
tice and future research. Nonetheless, there are some shortcomings 
to acknowledge. First, only one electronic database was extensively 
examined to identify relevant literature. In this regard, however, it is 
worth noticing that the search strategy was comprehensive, includ-
ing several terms to consider the similarities with FIRES reported 
under different diagnoses over decades, and additional data were 
sought at the NORSE institute website, which is a dedicated source 
for medical professionals providing references to both published 
studies and non- peer- reviewed conference abstracts and updated 
reading lists on NORSE and FIRES curated by experts in the field. A 
further major limitation is that the characteristics of available data 
such as retrospective observational studies, case series and case 
reports with a high risk of bias were included. Because NORSE can 
be defined in the absence of a clear acute or active structural, toxic 
or metabolic cause within the related time window, the risk of fail-
ing to appropriately apply the diagnostic criteria due to the retro-
spective study design should be considered. Importantly, there was 
great heterogeneity in the diagnostic work- up used both between 
and within the studies. Further, included studies were performed 
in both high- and middle- or low- income countries, and over a time 
frame of more than four decades. The lack of standardized diagnos-
tic protocols and differences in healthcare resources and scientific 
knowledge at the time each study was performed may have been a 
source of bias and heterogeneity in the diagnostic yield of studies. 
Missing the identification of a specific aetiology leading a case of 
NORSE to be labelled as ‘cryptogenic’ may, hence, rely on the nature 
and extent of the diagnostic investigations carried out in individual 
cases. At the same time, the publication bias in favour of those cases 
where a cause underlying the clinical presentation was detected 
needs to be considered. In addition, only a few large case series of 
adult and paediatric patients presenting with NORSE were included 
and used to estimate the actual frequency of the different aetiolo-
gies. As not every case series provided individual patient data, it was 
not possible to perform a quantitative synthesis on demographics, 
aetiologies and treatments pooling together results from the differ-
ent studies.
CONCLUSION
Far from being a unitary condition or entity, NORSE is a heterogene-
ous and clinically challenging presentation with varied causes, which 
remain unidentified in many cases.
It is noteworthy that, despite the high prevalence of autoimmune 
or paraneoplastic aetiologies, one survey involving 107 neurocritical 
care practitioners in the USA about the diagnostic and therapeu-
tic approach to NORSE revealed that about two- thirds of institu-
tions did not employ a protocol to evaluate patients, one- quarter of 
respondents would not perform an autoimmune or paraneoplastic 
assessment in the absence of a suggestive history or physical ex-
amination, and most sent antineuronal antibody studies only as part 
of an extended work- up; in addition, 29% of respondents reported 
they would never use intravenous immunoglobulin and 24% would 
not use plasma exchange [94].
Finally, although outside the scope of this review, it is worth 
mentioning that there are preliminary findings about the effective-
ness of new candidates as treatments throughout the SE continuum, 
including anti- cytokine therapies and neuroactive steroids, and ad-
ditional more solid evidence is necessary [41– 44,71,95– 97].
The issues highlighted in this comprehensive systematic review 
underlie the need for better and consistent research on the topic. 
The following are suggested.
 1. Further research is warranted to recognize clinical character-
istics that may point early to a specific aetiology and suggest 
what treatment strategy will be most effective.
 2. Analyses of larger case series where individual patient data are 
available may allow any associations between individual aetiolo-
gies, response to treatment and outcome to be explored.
 3. Prospective studies based on standardized eligibility and diag-
nostic criteria, adopting a standardized diagnostic work- up, and 
recruiting a larger population would allow the actual frequency 
of aetiologies of NORSE to be estimated and possible associa-
tions with clinical presentation to be identified.
 4. Multicentre registries could offer the opportunity to speed up 
the prospective collection of data to analyse and interpret in a 
timely fashion.
 5. Retrospective analyses may be useful to identify still unappreci-
ated causes for NORSE and generate testable hypotheses for 
further scrutiny. Hospitals should be encouraged to store first 
obtained CSF, urine and serum for at least a month at – 20°C or 
at – 80°C, and in those cases with prolonged RSE (>7 days) for 
5– 10 years to allow for retrospective analysis when new data 
become available.
 6. Protocols to standardize diagnostic work- up should be devel-
oped to increase the diagnostic yield and guarantee the prompt 
recognition of NORSE.
 7. Protocols to guide therapeutic approaches according to the ae-
tiology underlying NORSE should be implemented to allow the 
reliable care of patients.
 8. Diagnostic and therapeutic guidelines should be shared across 
scientific communities and working groups, and dissemination 
of clinical decision support tools may decrease the time to diag-
nosis and treatment.
 9. Planning and advancing strategies to identify barriers, facilita-
tors and resources to make sustainable diagnostic interventions 
possible across healthcare settings should accompany advanc-
ing scientific knowledge.
 10. Global cooperation and multicentre research represent priori-
ties of the road map to improve the understanding and manage-
ment of NORSE.
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